NASDAQ: ELTX
Elicio Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ELTX

Based on 1 analyst offering 12 month price targets for Elicio Therapeutics Inc

Min Forecast
$10.00+31.58%
Avg Forecast
$10.00+31.58%
Max Forecast
$10.00+31.58%

Should I buy or sell ELTX stock?

Based on 1 analyst offering ratings for Elicio Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ELTX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ELTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ELTX stock forecasts and price targets.

ELTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-02

1 of 1

Forecast return on equity

Is ELTX forecast to generate an efficient return?

Company
N/A
Industry
140.91%
Market
90.47%

Forecast return on assets

Is ELTX forecast to generate an efficient return on assets?

Company
N/A
Industry
32.45%

ELTX earnings per share forecast

What is ELTX's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$2.58
Avg 2 year Forecast
-$2.66

ELTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELTX$7.60$10.00+31.58%Buy
SEER$2.07N/AN/A
TARA$3.14$19.75+528.98%Strong Buy
GLSI$9.20$39.00+323.91%Buy
CCCC$1.68$12.00+614.29%Strong Buy

Elicio Therapeutics Stock Forecast FAQ

Is Elicio Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ELTX) stock is to Buy ELTX stock.

Out of 1 analyst, 0 (0%) are recommending ELTX as a Strong Buy, 1 (100%) are recommending ELTX as a Buy, 0 (0%) are recommending ELTX as a Hold, 0 (0%) are recommending ELTX as a Sell, and 0 (0%) are recommending ELTX as a Strong Sell.

If you're new to stock investing, here's how to buy Elicio Therapeutics stock.

What is ELTX's earnings growth forecast for 2025-2026?

(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Elicio Therapeutics's earnings in 2025 is -$51,280,000.On average, 1 Wall Street analyst forecast ELTX's earnings for 2025 to be -$41,272,198, with the lowest ELTX earnings forecast at -$41,272,198, and the highest ELTX earnings forecast at -$41,272,198.

In 2026, ELTX is forecast to generate -$42,551,956 in earnings, with the lowest earnings forecast at -$42,551,956 and the highest earnings forecast at -$42,551,956.

What is ELTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ELTX) forecast ROE is N/A, which is considered weak.

What is ELTX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ELTX price target, the average ELTX price target is $10.00, with the highest ELTX stock price forecast at $10.00 and the lowest ELTX stock price forecast at $10.00.

The Wall Street analyst predicted that Elicio Therapeutics's share price could reach $10.00 by Apr 2, 2026. The average Elicio Therapeutics stock price prediction forecasts a potential upside of 31.58% from the current ELTX share price of $7.60.

What is ELTX's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ELTX) Elicio Therapeutics's current Earnings Per Share (EPS) is -$3.92. On average, analysts forecast that ELTX's EPS will be -$2.58 for 2025, with the lowest EPS forecast at -$2.58, and the highest EPS forecast at -$2.58. In 2026, ELTX's EPS is forecast to hit -$2.66 (min: -$2.66, max: -$2.66).

What is ELTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ELTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.45%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.